ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1825

Osteoprotegerin Is Associated with Lupus and with Coronary Artery Calcification

Indu Poornima1, Kelly J. Shields2, Susan Manzi3, Rosalind Ramsey-Goldman4, Carrie Richardson5, Lewis Kuller6, George Kondos7, James Carr5, Craig Langman5, Heather Price5, Daniel Edmundowicz8 and Rachel Mackey9, 1Division of Cardiology, Allegheny Health Network, Pittsburgh, PA, 2Rheumatology, Allegheny Singer Research Institute, Pittsburgh, PA, 3Rheumatology, Allegheny Health Network, Pittsburgh, PA, 4Northwestern University Feinberg School of Medicine, Chicago, IL, 5Northwestern University, Evanston, IL, 6Epidemiology, University of Pittsburgh, Pittsburgh, PA, 7University of Illinois in Chicago, Chicago, IL, 8Cardiology, Temple University School of Medicine, Philadelphia, PA, 9Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: coronary artery disease and osteoprotegerin, Lupus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: In the general population, we and others have reported that higher osteoprotegerin (OPG), a protein involved in bone remodeling, is associated with higher levels of coronary artery calcification (CAC).  Higher levels of OPG have been reported in SLE associated bone fractures and nephritis. We have previously reported higher CAC in  women with systemic lupus erythematosus (SLE) vs. healthy controls (HC) in two SLE case-control studies, HEARTS and SOLVABLE but the association of OPG with CAC in SLE is unknown.  Therefore we hypothesized that in HEARTS and SOLVABLE, higher serum OPG would be associated with the higher levels of CAC seen in SLE.

Methods: Levels of OPG were assayed by ELISA in frozen samples of plasma (HEARTS) and serum (SOLVABLE).  CAC was measured by CT in both studies and ordinal logistic regression models were used to estimate adjusted ORs for being in a higher CAC category (0, 1-10, 11-100 and >100) vs. the next lower category. 

Results:

Combining HEARTS (n cases /controls=125/124, age and race-matched) and SOLVABLE (n cases/controls= 185/184, age and race-matched), mean age (for cases, controls) was 46, 48 years, % postmenopausal (45, 40%), % African-American (AA) (23, 22%), %current smoking (11, 10%) and %ever smoking (37, 44%).  The distribution of CAC among the 620 women was CAC=0: n=397 (218 HC and 179 SLE), CAC=1-10: n=109 (52 HC, 57 SLE), CAC 11-100: n=64 (29 HC, 35 SLE) and CAC>=100: n= 43(9 HC, 34 SLE.) In both studies, OPG was higher for SLE vs. HC, AA vs. white, and post- vs. premenopause (p<0.05).  Among the entire group, OPG was higher with higher CAC category, with OR (95%CI) = 1.35(1.14, 1.59) per SD OPG and 2.21(1.32, 3.71) for the 4th vs. 1stquartile of  OPG (Q4 vs. Q1).  Based on the racial differences noted in OPG levels, subgroup analyses were conducted by race and case-control status, showing a consistent positive association for white HC and SLE and AA HC. However, among AA SLE cases (n=67), there was no association of OPG with higher CAC (OR=1.0, p=0.9).  Therefore all subsequent analyses excluded AA SLE cases in models adjusted for study, race, LDL-C and smoking.  Higher OPG was significantly associated with higher CAC category for SLE cases, OR (95%CI) for Q4 vs. Q1= 2.80 (1.25-6.30) and for HC: 2.40 (1.03, 5.58), in separate models.   Among the entire group (HC+SLE), the OR for Q4 vs Q1 OPG in predicting higher CAC was 2.78 (1.57, 4.94), and with adjustment for SLE, was 2.72 (1.53, 4.84).  For SLE vs. HC, the OR for higher CAC was 2.20 (1.47, 3.29), and 2.14 (1.43, 3.22) when adjusted for OPG (quartiles).   Results were similar in sensitivity analyses restricted to HEARTS only, or white women only, or white post-menopausal women only.

Conclusion:

In 2 SLE case-control studies, higher OPG was associated both with SLE and with higher CAC among cases and controls, except for AA SLE cases. The association of SLE with higher CAC was only slightly attenuated by concurrent levels of OPG.  Longitudinal studies in larger samples are warranted to clarify the role of OPG in the increased CAC noted in SLE, and potential differences by race.


Disclosure: I. Poornima, None; K. J. Shields, None; S. Manzi, Bristol-Myers Squibb, 2,Bristol-Myers Squibb, 2; R. Ramsey-Goldman, None; C. Richardson, None; L. Kuller, None; G. Kondos, None; J. Carr, None; C. Langman, None; H. Price, None; D. Edmundowicz, None; R. Mackey, None.

To cite this abstract in AMA style:

Poornima I, Shields KJ, Manzi S, Ramsey-Goldman R, Richardson C, Kuller L, Kondos G, Carr J, Langman C, Price H, Edmundowicz D, Mackey R. Osteoprotegerin Is Associated with Lupus and with Coronary Artery Calcification [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/osteoprotegerin-is-associated-with-lupus-and-with-coronary-artery-calcification/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/osteoprotegerin-is-associated-with-lupus-and-with-coronary-artery-calcification/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology